Eli Lilly and Company announced that the FDA approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe… read more.
Priovant Therapeutics announced the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults… read more.
The first clues that a baby may develop eczema or food allergies could be hiding in the microscopic organisms living on their skin, according to a study led… read more.
Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like… read more.
Knight Therapeutics Inc. announced the launch of Wynzora, a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada…. read more.
A new study of sunscreens, baby lotions, shampoos, soaps, and other everyday products found that nearly all contained chemicals not disclosed on their labels. Most contained at least one unlabeled… read more.
Arcutis Biotherapeutics announced that the FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.
New peer-reviewed publications find significant gaps in lip product regulation and safety testing, including reliance on inappropriate skin models and significant underestimation of usage and ingestion rates, leaving… read more.
AbbVie announced that the EC has approved Rinvoq (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older… read more.
Arcutis Biotherapeutics announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.05% to expand the indication for the topical treatment of… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved remibrutinib (Rhapsido) 25 mg film-coated tablets for the treatment of adults with chronic spontaneous urticaria (CSU) whose symptoms… read more.
Incyte announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
